Tazemetostat showed a 54% disease control rate at week 12 for patients with BAP1-inactivated malignant pleural mesothelioma, with some partial responses observed but no confirmed complete responses [63]. This evidence concerns the gene BAP1 and malignant pleural mesothelioma.